Janssen touts Transposagen technology in CAR-T collaboration
This article was originally published in Scrip
Transposagen Biopharmaceuticals doesn't make a big public fuss about its pharmaceutical collaborations – the Lexington, Kentucky-based company has relationships with 19 out of the top 20 big pharma – but the Johnson & Johnson subsidiary Janssen Biotech is happy to tout the promise of its new partner's technology.
You may also be interested in...
Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.